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Abstract 27 
Despite available antibiotic therapy, pneumococcal meningitis (PM) is associated with a case fatality 28 
rate of up to 30% in high-income countries. Survivors often suffer from severe lifelong disabilities. An 29 
excessive inflammatory reaction drives the pathophysiology leading to brain damage and neurologic 30 
sequelae. We aimed to improve the outcome of experimental PM by simultaneously targeting different 31 
pathophysiological mechanisms with combined adjunctive therapies previously shown to be 32 
neuroprotective. In vitro, the anti-inflammatory effect of doxycycline and daptomycin were evaluated 33 
on primary rat astroglial cells stimulated with S. pneumoniae. Eleven day old infant Wistar rats were 34 
infected intracisternally with S. pneumoniae and randomized for treatment with ceftriaxone or 35 
combination adjuvant therapy consisting of ceftriaxone, daptomycin and doxycycline. During acute 36 
PM, combined adjuvant therapy with ceftriaxone, daptomycin and doxycycline increased survival rate 37 
from 64.1% to 85.8% (p<0.01) and alleviated weight loss compared to ceftriaxone monotherapy 38 
(p<0.01). Levels of inflammatory cytokines were significantly reduced by combined adjuvant therapy 39 
in vitro (p<0.0001) and in cerebrospinal fluid in vivo (p<0.05). In infected animals treated with 40 
combined adjunctive therapy, cortical damage was significantly reduced (p<0.05) and they showed a 41 
trend towards better hearing capacity three weeks after the infection (p=0.089), an effect which was 42 
significant in mildly infected animals (48dB vs 67.22dB, p<0.05). These mildly infected animals 43 
showed significantly reduced cochlear fibrous occlusion (p<0.01). By combining non-bacteriolytic 44 
daptomycin and anti-inflammatory doxycycline with ceftriaxone, their previously reported beneficial 45 
effects were cumulated and identified the triple antibiotic therapy as a promising therapeutic option for 46 
paediatric PM.  47 
Key words 48 
Pneumococcal meningitis, brain injury, neurologic sequelae, neuroinflammation, hearing loss, 49 
combination adjuvant therapy 50 
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Introduction 52 
Acute bacterial meningitis is a severe illness with high mortality and morbidity – especially when 53 
acquired during infancy or childhood – causing long-lasting neurofunctional deficits (e.g. hearing loss, 54 
epilepsy, cerebral palsy and cognitive deficits), which tremendously influence quality of life in 55 
affected children (1–6). Currently, Neisseria meningitidis and Streptococcus pneumoniae are the most 56 
prevalent etiological agents for childhood meningitis beyond the neonatal age, as Haemophilus 57 
influenza type b has been nearly eradicated since vaccine introduction (7). In high-income countries, 58 
meningitis caused by S. pneumoniae and N. meningitidis presents case-fatality rates of 30% and 7%, 59 
respectively (6, 8). Fatality rates are reported to be as high as 50% in resource-poor setting (9). The 60 
risk for neurologic sequelae is especially high after pneumococcal meningitis (PM) (3), which causes a 61 
massive infection of the central nervous system (CNS) with associated cortical necrosis and apoptosis 62 
of dentate gyrus granular cells progenitors in the hippocampus, as found in human patients (10) and 63 
animal models (11–14). Neural cell death is caused by multiple factors including bacterial toxins and 64 
an excessive inflammatory reaction from the host (15–17). Together with the recruited neutrophils, 65 
activated brain-resident microglia are able to produce large quantities of inflammatory cytokines, 66 
reactive oxygen and nitrogen species (ROS and RNS), helping to eradicate the pathogen but also 67 
contributing to the development of neuronal damage (15, 18, 19). Pathological cell death in the 68 
hippocampus during acute PM correlates with learning and memory deficits  (20–23). Furthermore, 69 
PM induces damage in the peripheral nervous system (PNS) characterised by sensorineural hearing 70 
loss caused by damage to hairs cells and spiral ganglion neurons in the inner ear (24–26), provoking 71 
hearing impairments in up to 30% of survivors (3, 4, 6). 72 
Clinical guidelines recommend the use of adjunctive dexamethasone – an anti-inflammatory 73 
corticosteroid – for adult PM in high income countries (27, 28). However, adjuvant dexamethasone 74 
failed to provide a beneficial effect on PM-induced mortality and hearing loss in children (27, 29) and 75 
even aggravated mortality, acute brain injury and long-term learning deficits in different experimental 76 
models of bacterial meningitis (23, 30, 31). Over the last few decades, alternative adjuvant therapies 77 
including antioxidants, complement inhibitors, non-bacteriolytic antibiotics or matrix 78 
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metalloproteinase (MMP) inhibitors, which target different pathophysiological mechanisms during 79 
acute PM were tested and have shown promising results in PM animal models (32–39). These 80 
therapies were mostly evaluated as single adjuvant therapies or in combination with dexamethasone 81 
(40, 41), being less relevant in paediatric meningitis. We recently postulated to combine successful 82 
single adjuvants to more effectively reduce CNS and PNS damage thereby improving long-term 83 
outcome by reducing neurologic sequelae after paediatric PM. This strategy was successfully tested in 84 
the same experimental model as described in this present study by combining daptomycin (DAP) and 85 
the matrix metalloproteinase inhibitor Trocade (42). An independent experimental study also reported 86 
beneficial effects of combining adjuvant therapies to improve acute and neurofunctional outcomes 87 
after murine PM (43).  88 
DAP has previously been shown to clear pneumococci from CSF more rapidly than ceftriaxone (CRO) 89 
without inducing bacterial lysis, thereby lowering the overall inflammatory burden in animal models 90 
(44, 45). DAP penetrates into the CSF – especially after neurological infection (46, 47) – and reaches 91 
5-11.5% of serum concentration mediating bactericidal effects (46–48). In infant rat PM, adjunctive 92 
daptomycin reduced neuroinflammatory cytokines in the cerebrospinal fluid (CSF) and decreased 93 
brain injury and hearing loss (32, 42). Apart from its antimicrobial activity, doxycycline (DOX) – 94 
which is known to penetrate well into the brain and CSF (49) – also has multiple anti-inflammatory 95 
effects by reducing cytokine release and inhibiting MMP activity (50–56). Adjuvant DOX reduced 96 
mortality and injury to the brain and cochlea in experimental infant rat PM (56),  similarly to other 97 
MMP inhibitors that were shown to reduce blood-brain barrier permeability, inflammatory cytokines 98 
in CSF, brain injury and mortality during acute bacterial meningitis (34, 42, 57, 58). 99 
By combining adjunctive DAP and DOX therapies, we intend to target multiple pathophysiological 100 
mechanisms responsible for brain injury during acute bacterial meningitis with the aim to integrate the 101 
beneficial effects of both substances and improve the neurofunctional outcome after paediatric PM. 102 
  103 
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Results 104 
Antibiotic susceptibility of S. pneumoniae serotype 3 105 
The MIC of ceftriaxone for the used S. pneumoniae serotype 3 was determined to be 0.003mg/L. 106 
MICs of daptomycin and doxycycline were both at 0.064mg/L. Determined MICs revealed 107 
susceptibility of our S. pneumoniae serotype 3 strain to assessed antibiotics according to published 108 
data (59, 60). 109 
Reduced release of inflammatory cytokines and nitric oxide in vitro 110 
Inflammatory cytokines and nitric oxide (NO) were measured in astroglial cell culture supernatant 24 111 
hours after concomitant application of living S. pneumoniae and antibiotics. Antibacterial but 112 
bacteriolytic therapy with CRO induced a strong release of inflammatory cytokines (IL-1β, IL-6, IL-113 
10 and TNF-α, Fig. 1 A-D) and NO (Fig. 1 E). After adjustment for multiple testing, DOX 114 
monotherapy significantly reduced the release of IL-1β (p<0.002), IL-6 (p<0.002), TNF-α (p<0.0001) 115 
and NO (p<0.001) compared to CRO monotherapy. Accordingly, CRO+DOX significantly decreased 116 
IL-6 (p<0.02), TNF-α (p<0.0001) and NO (p<0.001) levels. DAP monotherapy and combination 117 
therapy with CRO+DAP reduced the inflammatory reaction to a greater extent with clearly lowered 118 
inflammatory cytokines – except IL-10 – (all p<0.0001 for CRO vs. DAP and CRO vs. CRO+DAP) 119 
and NO release (p<0.0001 for all combinations containing DAP). Notably, combined triple therapy 120 
with CRO+DOX+DAP significantly decreased the release of IL-1β, IL-6, TNF-α and NO (all 121 
p<0.0001 for CRO+DOX+DAP vs. CRO) and was the only therapy to significantly reduce IL-10 122 
concentrations compared to CRO monotherapy (p<0.03). S. pneumoniae exposure did not induce a 123 
visible cytopathic effect on astroglial cells in any of the treatment groups, as determined by the 124 
observation of intact monolayers (data not shown). Therefore, the reported reduction of NO and 125 
cytokine production upon DOX and/or DAP therapy cannot be associated to an increased cell death 126 
within these groups. 127 
Improved survival and increased weight gain in infant rats with PM 128 
A total of 156 infant Wistar rats were enrolled for this study. One animal was excluded after 129 
unsuccessful infection with no detectable bacterial CSF titer at 18 hpi. All other infected animals were 130 
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included after having fulfilled at least one criterion for successful infection (positive bacterial CSF 131 
titer > 106 cfu/ml, reduced clinical score, weight loss, changes in posture). 132 
Infected rats showed reduced survival compared to uninfected controls (Fig. 2 A). Animals receiving 133 
the combination adjuvant therapy, demonstrated a significant better survival compared to infected rats 134 
with CRO monotherapy (85.8 % vs. 64.1%, long-rank p=0.0052). Compared to uninfected controls, 135 
which constantly gained weight within 42 hours after mock-infection, animals with PM showed only a 136 
slight weight increase within the first 18 hours (Fig. 2 B). Thereafter, infected animals treated with 137 
CRO monotherapy lost weight (2.81 % weight loss at 42 hpi). This weight loss was reduced with 138 
combined adjuvant therapy (0.8% weight gain at 42 hpi), resulting in a significantly higher relative 139 
weight gain compared to infected animals with CRO monotherapy (p=0.0022). At all measured time 140 
points, uninfected animals gained significantly more weight than their infected counterparts, 141 
independent of treatment modality (p<0.0001). Upon infection, clinical scores were reduced and 142 
reached a minimum at 24 hpi, whereas uninfected animals did not show any changes in clinical scores 143 
at any time point (Fig. 2 C). Clinical scores of infected animals treated with combination adjuvant 144 
therapy showed a trend to be higher compared to infected animals receiving CRO monotherapy at 24 145 
hpi (p=0.0884). From 24 hpi on, infected rats started to recover and showed an improvement in 146 
clinical scores at 42 hpi, still being significantly lower than those of uninfected control animals 147 
(p=0.0015 for CRO and p=0.0053 for CRO+DOX+DAP).  148 
Reduction of inflammatory parameters in CSF in vivo 149 
Inflammatory cytokines were measured in the CSF of infected animals before and at 6 and 24 hours 150 
after treatment initiation (representing 18, 24 and 42 hpi). Before treatment, cytokine levels were 151 
comparable between the two infected groups. Compared to animals treated with CRO monotherapy, 152 
IL-1β and IL-10 CSF levels were significantly reduced in rats receiving the combination adjuvant 153 
therapy six hours after treatment initiation (p=0.0004 and p=0.0128, Fig. 3 A and C). IL-6 and TNF-α 154 
revealed a trend towards reduced CSF levels (p=0.071 and p=0.076, Fig. 3 B and D). Twenty-four 155 
hours after therapy start, IL-6 was significantly lower in animals receiving combined adjuvant 156 
interventions (p=0.0139, Fig. 3 B). IFN-γ levels were similar between the two groups at all time points 157 
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(data not shown). Before therapy initiation, bacterial CSF titers were not different with 1.09 ± 0.71 x 158 
108 cfu/ml in the CRO group and 1.15 ± 1.26 x 108 cfu/ml in the CRO+DOX+DAP group (p=0.772). 159 
Six hours after therapy begin, all animals treated with the combined adjuvant intervention had 160 
undetectable bacterial titers (<102 ± 0 cfu/ml), whereas half of the animals receiving CRO 161 
monotherapy still showed detectable but very low bacterial titers in CSF (3.06 ± 0.89 x 102 cfu/ml), 162 
representing a significantly faster bacterial clearance in CSF with combined adjuvant therapy 163 
(p=0.0236, Fig. 3 E). 164 
Reduced cerebral complication in vivo 165 
PM-induced cerebral damage was assessed in all animals sacrificed at 42 hpi. Cortical necrosis was 166 
only found in animals with PM.  Its extent was significantly higher in the group treated with CRO 167 
monotherapy compared to animals receiving combined adjuvant therapy (0.73 % [IQR 0-9.7, n=15] 168 
vs. 0% [IQR 0-0, n=15] p=0.0302, Fig. 3 F). Elevated levels of hippocampal apoptosis were only 169 
found in infected animals (data not shown). Here, however, no differences between the two treatment 170 
groups were found (CRO monotherapy: 0.89 ± 0.91, n=13 vs. CRO+DOX+DAP therapy: 0.92 ± 1.26, 171 
n=15 apoptotic cells per visual field, p=0.943). 172 
Improvement of hearing capacity three weeks after infection 173 
To investigate long-term neurologic sequelae induced by PM, hearing capacity was assessed by 174 
auditory evoked brainstem response (ABR) three weeks after infection. Representative ABR 175 
recordings from a control animal and an infected rat are shown in figure 4 A and B, respectively. 176 
Control animals showed detectable responses down to 35 dB, whereas the infected animal did not 177 
show any measurable signal below 65dB (Fig. 4 A and B). The average hearing threshold was 38.13 ± 178 
2.39 dB or 38.75 ± 1.44 dB in uninfected animals that received CRO monotherapy or combined 179 
adjuvant therapy, respectively (Fig. 4 C). Compared to uninfected rats, infected animals showed 180 
significantly higher average hearing thresholds, irrespective of therapy regimen. Treatment with 181 
combined adjuvant therapy showed a trend for improved hearing capacity compared to CRO 182 
monotherapy (63.26 ± 23.9 dB vs. 72.88 ± 24.8 dB, p=0.0891, Fig. 4 C) in infected rats. In 183 
experiments with severely infected animals (defined as an in-litter mortality > 15%), severe hearing 184 
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loss (average hearing threshold ≥ 80 dB) was observed, with no difference between therapies. When 185 
considering only experiments with an in-litter mortality of less than 15% (mild infection experiments), 186 
combination adjuvant therapy with DAP and DOX – compared to CRO monotherapy – significantly 187 
reduced PM-induced hearing loss (48.00 ± 21.7 dB, n=10 vs. 67.22 ± 25.9 dB, n=9, p=0.0482).  188 
Univariate linear regression (table 1) analysis revealed significantly increased hearing threshold with 189 
increasing bacterial inoculum (70.5 dB per additional log of infection inoculum, p<0.001). Low in-190 
litter mortality and higher clinical score at 24 hpi were both found to predict attenuation of PM-191 
induced hearing impairments (-18.1 dB in case of mildly infected animals, p=0.011; -26.7 dB per 192 
additional point of activity score at 24 hpi, p<0.001). Multivariate linear regression modelling (table 1) 193 
– including infection inoculum, litter mortality and treatment regimen – displayed comparable 194 
findings. After adjusting for in-litter mortality and bacterial inoculum, combination adjuvant therapy 195 
was found to significantly reduce PM-induced hearing loss by 10.3 dB (p=0.037). 196 
Improved hearing is associated with reduced fibrous occlusion of the perilymphatic 197 
space 198 
To investigate the reason for improved hearing capacity in mildly infected rats treated with 199 
combination adjuvant therapy, histomorphological damage in inner ear was assessed by 200 
immunofluorescence. Previous work showed that PM-induced hearing loss was accompanied by 201 
reduced spiral ganglion neuron density in the cochlea – being a critical predictor for the efficacy of a 202 
cochlear implant (25). Spiral ganglion neurons were quantified in the basal, middle and apical turn of 203 
mildly-infected animals, as indicated in figure 5 A. No statistical differences were found between the 204 
two treatment groups at any of the cochlear turns (fig. 5 C). In the present study, only few animals 205 
showed a reduction in SGN density (< 2000 TUJ+ cells/mm2, e.g. left middle turn in Fig. 5 A), as 206 
compared to SGN density previously reported in mock-infected animals (25). Histomophological 207 
assessment of the cochlear turns revealed extensive fibrous occlusion of the perilymphatic space in 208 
infected animals (Fig. 5 B). Fibrous occlusion was significantly reduced in infected animals treated 209 
with the combined adjuvant intervention compared to animals receiving CRO monotherapy (Fig. 5 D). 210 
In mildly-infected animals, a significant positive correlation was found for fibrous occlusion of the 211 
perilymphatic space and hearing threshold (Fig. 5 E, r=0.5051, p=0.0274). 212 
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Discussion 213 
Observational clinical studies repetitively found neurologic sequelae in patients surviving bacterial 214 
meningitis, with especially high risk after PM (3). A profound inflammatory reaction in the CNS and 215 
PNS is associated with cortical necrosis, hippocampal apoptosis and cochlear damage (11–13, 24–26). 216 
In addition to bacterial toxins, the host’s excessive inflammatory reaction contributes to the observed 217 
neural cell death (15–17). Bacterial autolysis and also bactericidal antibiotics with antibiotic-218 
dependent lysis of bacteria provoke a release of highly immunogenic products, promoting 219 
inflammatory processes and disease severity (15, 61–64). During PM, secreted MMPs from activated 220 
immune cells are crucially upregulated and associated with brain injury (15, 34, 65) with higher 221 
MMP-9 level being associated with the development of hearing impairment or secondary epilepsy in 222 
infected children (65). By degrading basal lamina components and tight junction proteins, MMP-9 223 
weakens the blood-brain-barrier (BBB) (58, 66–68) and facilitates leukocyte extravasation and BBB 224 
leakage (33, 69). Additionally, MMPs contribute to the inflammatory reaction and brain injury via 225 
their sheddase and convertase activity, being able to cleave and activate inflammatory cytokines and 226 
chemokines (33, 70–72).  227 
DOX has multiple anti-inflammatory effects by reducing cytokine release and inhibiting MMP activity 228 
(50–56). Pharmacologic inhibition of MMPs during acute bacterial meningitis resulted in the reduction 229 
of blood-brain barrier permeability, inflammatory cytokine levels in CSF, brain injury and mortality 230 
(34, 42, 57, 58). Selective MMP inhibitors (e.g. BB-94, BB-1101, GM-6001 or TNF-484) have not yet 231 
been successfully tested in clinical studies. DOX, on the other hand, has a well-characterized clinical 232 
safety profile (56). The herein used dosage of DOX was previously shown by others to suppress 233 
cerebral MMP-9 activity and reduce ischemic brain damage in rodents (73, 74). In experimental infant 234 
rat PM, adjuvant DOX reduced mortality and injury to the brain and cochlea (56).  235 
DAP, a non-bacteriolytic but bactericidal antibiotic, integrates itself into the bacterial cell membrane,  236 
induces its depolarisation and biosynthesis inhibition (75–77). In previous work, we demonstrated a 237 
faster bacterial clearance from CSF with DAP leading to reduced inflammatory parameters and 238 
decreased cortical complication compared to standard CRO therapy in infant rat PM (45, 78). In the 239 
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same infant rat PM model, adjunctive DAP to CRO reduced PM-associated cerebral damage, 240 
inflammatory cytokine levels in the CSF and improved hearing capacity (32, 42). In adult rats with 241 
PM, DAP treatment attenuated cognitive impairment in surviving rats compared to CRO (79). 242 
Our previous work on the herein reported experimental model – but also other independent 243 
experimental work – confirmed the potential of combined adjuvant interventions targeting multiple 244 
pathophysiological mechanisms during PM, thereby improving acute and neurofunctional outcomes 245 
(42, 43). With this study, we were able to show that combined adjuvant therapies in experimental 246 
paediatric PM cumulate previously reported beneficial effects of single adjuvants and significantly 247 
improve acute neuropathology and neuroinflammation, thereby improving neurofunctional outcome 248 
compared to standard CRO monotherapy. Combined adjuvant therapy with DAP and DOX was able to 249 
improve survival and weight gain in infant rats infected with S. pneumoniae (Fig. 2 A, B). Adjuvant 250 
DOX – but not DAP – previously demonstrated its capacity to significantly improve survival among 251 
infant rats with PM (32, 56). Tetracyclines also demonstrated mortality reduction in experimental 252 
sepsis models (80). On the other hand, adjuvant DAP was beforehand shown to improve weight 253 
change after treatment initiation (32). Herein, adjuvant combination therapy with DOX and DAP 254 
significantly reduced inflammatory cytokines in CSF in vitro and in vivo (Fig. 1 and 3). Despite 255 
previous findings, which showed reduced CSF levels of TNF-α upon DOX-induced TACE inhibition 256 
(56) and reduced CSF IL-6 levels with adjuvant DAP (32), we only found statistical trends toward 257 
lower CSF levels of these cytokines six hours after treatment initiation (Fig. 3 B,D). Of note, animals 258 
treated with combined adjuvant therapy showed slightly higher initial TNF-α and IL-6 levels (18 hpi) 259 
with faster subsequent reduction after therapy initiation. In other experimental inflammatory diseases, 260 
DOX was shown to inhibit interleukin-converting enzyme, thereby lowering the bioavailability of IL-261 
1β (56, 81). In accordance with this data, we found significantly reduced IL-1β levels six hours after 262 
initiating therapy in vivo with combined adjuvant intervention compared to CRO monotherapy. 263 
Therapy initiation with CRO monotherapy caused increased CSF levels of IL-1β and IL-6, indicating 264 
that bacterial burst by lytic antibiotic further aggravates cerebral inflammation (44, 45, 63), which we 265 
were able to inhibit with adjuvant non-bacteriolytic DAP in vitro and in vivo. Our in vitro model of 266 
neuroinfection and neuroinflammation with primary rat astroglial cells supported the concept of 267 
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induced neuroinflammation upon therapy initiation with a bacteriolytic antibiotic with clearly reduced 268 
inflammatory cytokines and NO release by treatment with non-bacteriolytic antibiotics (Fig. 1). The 269 
reduced induction of neuroinflammation in vitro by simultaneous application of CRO+DAP (and 270 
CRO+DOX+DAP) underlines previous findings showing fast antibacterial action of DAP (45) and 271 
thereby supports the concept of DAP’s anti-inflammatory actions even when applied concomitantly 272 
with CRO.  273 
Animals receiving combined CRO+DOX+DAP showed significantly reduced cortical damage 42 hpi 274 
(Fig. 3 F), without showing a better outcome in terms of hippocampal apoptosis (not shown). The 275 
reduced cortical complication might be attributed to the overall reduction of CSF inflammation, as 276 
previously found by single adjuvant DAP and DOX therapy (32, 56).  277 
Combined adjuvant therapy with CRO+DOX+DAP improved hearing thresholds in mildly infected 278 
infant rats (Fig. 4 D), whereas severely infected animals showed profound hearing loss (average 279 
hearing threshold ≥ 80 dB), which might be beyond potential protection. These data were confirmed 280 
by a multivariate linear regression showing that after adjusting for infection inoculum and high in-281 
litter mortality, rats with combined adjuvant therapy revealed improved hearing capacity by 10.3 dB 282 
(Table 1). Histologic analysis revealed that spiral ganglion neuron density was not significantly 283 
affected in mildly infected rats (Fig. 5 C) compared to previously published data of mock-infected 284 
infant rats (25). Improved hearing capacity in animals with combined adjuvant therapy was correlated 285 
to a significant reduction of fibrous occlusion of the perilymphatic space (Fig. 5 D, E). Fibrous 286 
obliteration of the perilymphatic space after experimental PM has been described in a mouse model of 287 
PM and positively correlated with increased hearing loss (37). During acute infection, leukocytes enter 288 
the perilymphatic space contributing to the inflammatory processes (26). Resolution of the 289 
granulocytic inflammation is expected to cause occlusion of the perilymphatic space with connective 290 
tissue, potentially leading to cochlear ossification (26). As cochlear ossification can limit the access 291 
for cochlear implantations (82), a reduction in fibrous obliteration with associated cochlear 292 
ossification has important clinical consequences. Of note, cochlear hair cells and presynaptic ribbons 293 
of surviving inner hair cells were not analysed during this study. The detected improvement in hearing 294 
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capacity with combined adjuvant DAP and DOX might also be attributed to a protection of cochlear 295 
hair cells or their connectivity to the SGNs. In previous work, we demonstrated that connectivity of 296 
inner hair cells to SGNs was already reduced after mild infection, whereas the inner hair cells 297 
themselves remained unaffected (25). In mildly infected animals with low level fibrotic occlusion, loss 298 
of inner hair cell connectivity might explain elevated hearing thresholds (Fig. 5 E).  299 
In a comprehensive meta-analysis, adjunctive anti-inflammatory corticosteroids were shown to 300 
improve the outcome of adults with PM in high income countries and children with meningitis caused 301 
by Haemophilus influenzae type b, without showing a clear benefit of corticosteroids in children with 302 
PM (27). Multiple experimental models of bacterial meningitis with adjunctive dexamethasone 303 
demonstrated aggravated mortality and acute hippocampal injury with subsequent learning and 304 
memory deficits, especially in infant rodents (23, 30, 31, 83, 84). As there is no substantial evidence 305 
for the use of dexamethasone in children with PM, we did not include it in our study focussing on 306 
paediatric PM. Further limitations of this study include the lack of direct comparison to single 307 
adjuvant therapies. As the respective single adjuvant therapies were already tested in our laboratory on 308 
the same model of PM, we decided to not include these therapy groups but to compare to previously 309 
reported data (32, 56). Additionally, we would like to mention the limitation of direct intracisternal 310 
inoculation of pneumococci to induce PM, which does not represent the pathophysiologic route of 311 
infection via the bloodstream (15). Yet, development of meningitis after intranasal inoculation with 312 
bloodstream spread and hematogenous CNS infection is only obtained is a small proportion of the 313 
infected animals – even after experimentally induced extracellular matrix degradation (85) – limiting 314 
the use of this inoculation method for specific research on meningitis. Furthermore, animals in our 315 
experiments were treated for 5 days and not 10-14 days as recommended for humans (28). Previous 316 
experiments showed, however, that this treatment duration resulted in a complete bacterial clearance 317 
with associated recovery of clinical scores and weight loss (25, 32, 42). Lastly, resulting CSF 318 
daptomycin levels of 0.5mg/L in patients with neurological infections (47, 86) are just slightly above 319 
the MIC for S. pneumoniae (60) and this may affect the beneficial effects seen in our animal model.”  320 
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Conclusion 321 
Combination adjuvant therapy with non-bacteriolytic DAP and DOX with its MMP-inhibitory and 322 
anti-inflammatory properties caused faster bacterial clearance and reduced inflammatory CSF cytokine 323 
levels, known to be mediators of brain damage during acute PM. Previously reported beneficial effects 324 
of these single adjuvants were merged together by combined intervention and improved survival, 325 
weight loss, cerebral complication and neurologic sequelae such as hearing loss. Therefore, we 326 
conclude that combining adjuvant DAP and DOX with CRO is a promising therapeutic option to 327 
improve the outcome of PM.  328 
  329 
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Material and Methods 330 
Infecting organism  331 
A clinical isolate of Streptococcus pneumoniae (serotype 3) from a patient with bacterial meningitis 332 
was cultured overnight in brain heart infusion (BHI) medium, diluted 10 fold in fresh, pre-warmed 333 
BHI medium, and grown for 5 h to reach the logarithmic phase as reported earlier (32, 58). The 334 
bacteria were centrifuged for 10 min at 3100 x g, washed twice and re-suspended in sterile, pyrogen-335 
free saline (NaCl 0.85%). Bacteria were further diluted to the desired density by measuring the optical 336 
density at 570nm (OD570). Inoculum accuracy was determined by serial dilutions and plating on 337 
Columbia sheep blood agar (CSBA) plates. 338 
Antibiotic susceptibility testing 339 
For MIC determination, blood agar plates were inoculated with S. pneumoniae serotype 3 – the strain 340 
used within this study. MICs of ceftriaxone (0.002-32mg/L; Liofilchem srl, Italy), doxycycline (0.016-341 
256 mg/L, bioMérieux, USA) and daptomycin (0.016-256 mg/L, bioMérieux, USA) were determined 342 
by using antibiotic gradient strips, according to the manufacturer’s protocol and as described before 343 
(45). 344 
In vitro model of neuroinfection and neuroinflammation 345 
Primary rat astroglial cells, isolated from the cortex and hippocampus of infant rats on post-natal day 3 346 
were kept in culture medium (DMEM [Sigma-Aldrich, Merck Switzerland] with 5% FCS [Biochrom, 347 
Germany], GlutaMAXTM [ThermoFisher, Switzerland] and antibiotic-antimycotic [ThermoFisher, 348 
Switzerland]) for 11 days at 37°C with 5% CO2, as reported elsewhere (87, 88). For stimulation 349 
assays, cells were seeded in poly-L-ornithine-coated 24-well plates and kept for additional 3 days. 350 
Subsequently, cell culture medium was replaced with phenol red-free and pyruvate-free DMEM 351 
(Gibco, ThermoFisher, Switzerland) with 5% FCS and GlutaMAXTM. Cells were stimulated with 3 x 352 
107 CFU/mL S. pneumoniae in logarithmic growth phase. Directly after stimulation with living 353 
bacteria, antibiotics were added to the cell culture medium (10µg/ml CRO [Rocephine, Roche)], 354 
1µg/ml DAP [Cubicin, Cubist Pharmaceuticals], 3µg/ml DOX [doxycycline hyclate, Sigma]), 355 
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reflecting CSF concentrations found in patients or experimental studies focusing on neuroinfections 356 
(46–49, 86, 89, 90). Nitric oxide production was measured using Griess reagent (Sigma-Aldrich, 357 
Merck Switzerland). Briefly, 100 µL Griess reagent was mixed with 100 µL cell culture medium in 358 
96-well plates. Absorbance was measured at 550 nm with a microplate reader (THERMOmax, 359 
Molecular Devices, USA). Nitrite concentrations were calculated from a NaNO2 standard curve.  360 
 361 
Infant rat model of pneumococcal meningitis 362 
All animal studies were approved by the Animal Care and Experimentation Committee of the Canton 363 
of Bern, Switzerland (license BE 129/14), and followed the Swiss national guidelines for the 364 
performance of animal experiments. A well-established infant rat model of PM was used for the 365 
experiments as previously described (32, 58). Eleven days old Wistar rats together with their dams 366 
were obtained from Charles River Laboratories (Sulzfeld, Germany). The dams were provided with 367 
tap water and pellet diet at libitum. Litters were kept in rooms at a controlled temperature of 22 ± 2 °C. 368 
During the acute phase of the disease, animals were housed in conventional cages in a room with 369 
natural light. For long-term experiments after bacterial curing, animals were transferred to individually 370 
ventilated cages (IVC) in a room with controlled 12-hour light/dark cycles. Intracisternal infections 371 
were performed by injection of 10 µl saline containing 7.33 ± 3.4 x 105 cfu/ml living S. pneumoniae. 372 
Mock-infected control animals received an equivalent volume of saline. Pneumococcal meningitis was 373 
confirmed 18 h post infection (hpi) by quantitative analysis of bacterial titers in CSF samples, when 374 
the animals developed symptomatic disease. For this, 5 µl of CSF were collected by puncture of the 375 
cisterna magna, followed by serial dilution and cultivation on columbia sheep blood agar (CSBA) 376 
plates. The infected animals were randomized for treatment with CRO (100mg/kg, Rocephine, Roche, 377 
twice daily [b.i.d]) plus: a.) combination adjuvant therapy (n=72) consisting of DAP (10 mg*kg-1 d-1, 378 
s.c. in saline, single dose; Cubicin, Cubist Pharmaceuticals) plus DOX (30mg/kg, i.p, once daily, 379 
Sigma, combined with CRO), or b.) saline in the control group (n=72). Antibiotic therapy with CRO 380 
was started at 18 hpi in all animals. Therapies involving DAP were started by the application of DAP 381 
followed by a 15 min-delayed application (i.e. at 18:15 hpi) of other therapies. For long-term 382 
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experiments assessing neurofunctional outcomes, CRO and DOX therapies were continued until day 5 383 
after infection. Mock-infected animals either received the combination adjuvant therapy (n=6) or the 384 
CRO monotherapy with vehicles (n=6). All animals received the same amount of fluids during the 385 
experiments.  386 
The rats were weighted and examined clinically at 0, 18, 24 hpi, and before sacrificing at 42 hpi, as 387 
previously described (58). Activity scores represent 1 = coma; 2 = does not turn upright; 3 = turns 388 
upright within 30 s; 4 = minimal ambulatory activity, turns upright in < 5 s; and 5 = normal. Weight 389 
was assessed relative to weight at time of infection (per cent increase). Investigators were blinded for 390 
treatment modalities. Spontaneous mortality was documented. Punctures of the cisterna magna were 391 
performed using a 30-gauge needle to obtain CSF samples at 18, 24, and 42 hpi. CSF samples not used 392 
for bacterial titer determination were centrifuged (16’000 x g at 4 °C for 10 min), and the supernatants 393 
were frozen at -80 °C until further use. Animals were sacrificed with an overdose of pentobarbital 394 
(150 mg/kg b.w., i.p  Esconarkon, Streuli Pharma AG, Uznach, Switzerland) at 42 hpi and perfused 395 
with ice-cold 4% paraformaldehyde (PFA) in phosphate-buffered saline (PBS) before their brains were 396 
removed and fixed in 4 % PFA for histological analysis. 397 
Histomorphometric assessment of cortical damage and hippocampal apoptosis 398 
Damage to cerebral structures was quantified as previously described in all animals sacrificed at 42 hpi 399 
(33, 91, 92). Briefly, brains were fixed in 4 % PFA and cryopreserved in 18 % sucrose in PBS at 4 °C 400 
overnight. Coronal brain cryosections (45 µm thick) obtained by systematic uniform sampling were 401 
stained for Nissl substance with cresyl violet. Cortical damage was defined as areas of decreased 402 
neuronal density. Histological features of apoptosis were quantified in 48 systematic visual fields 403 
spanning the hippocampus of both hemispheres. Histologic assessments were performed and evaluated 404 
by a person blinded to treatment modalities. 405 
Quantitative analysis of cytokine levels in the CSF 406 
A panel of cytokines previously found to be upregulated in PM (15, 93) – i.e. IL-1β, IL-6, TNF-α, IL-407 
10 and IFN-γ – was assessed using a magnetic multiplex assay (Rat Magnetic Luminex®  Assay, 408 
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R&D Systems, Bio-Techne) and a Bio-Plex 200 station (Bio-Rad Laboratories) as previously 409 
described (25, 33). Undiluted cell culture supernatant or five microliters of CSF harvested and 410 
centrifuged at 18, 24 and 42 hpi were diluted to a final volume of 50 µl using the provided assay 411 
buffer. At least 50 beads were measured for each analyte. Calibration curves from recombinant 412 
standards were calculated with Bio-Plex Manager software (version 4.1.1) using a five-parameter 413 
logistic curve fitting. For samples below the detection limit, the value of detection limit provided by 414 
the manufacturer (TNF-α, 22.1 pg/ml; IL-6, 56.0 pg/ml; IL-1β, 26.7 pg/ml; IL-10, 18.6 pg/ml; IFN-γ, 415 
70.5 pg/ml) was multiplied by the dilution factor. 416 
Click- and pure tone-evoked auditory brainstem response  417 
Auditory brainstem responses (ABRs) were recorded in response to click stimulations and pure tones 418 
on both ears using the SmartEP system (Intelligent Hearing Systems, Miami, USA), as previously 419 
described (25). Animals were anesthetized with isoflurane (5 % for induction and 2 % for 420 
maintenance) using the Combi-Vet Vaporizer System equipped with a digital flowmeter (Rothacher 421 
Medical, Switzerland). 100 µs click stimuli and five millisecond pure tone pips (Blackman envelope; 422 
polarity alternating) were presented at a rate of 21.1 s-1, ranging from 100 to 20 dB SPL in 10 dB 423 
decrements (5 dB decrements close to threshold). A total of 1024 responses were averaged at each 424 
sound level and filtered between 100 and 1500 Hz. The hearing threshold was defined as the lowest 425 
intensity that induced the appearance of a visually detectable first peak. ABRs were recorded between 426 
P30 to P34. Hearing thresholds were independently analysed and discussed by multiple blinded 427 
investigators. 428 
Immunohistological analysis of spiral ganglion neuron density and cochlear occlusion 429 
Immunohistological analysis of the cochlea was performed as reported earlier (25). In summary, three 430 
weeks after infection, the animals were sacrificed and perfused with 4% paraformaldehyde (PFA). 431 
Cochleas were dissected and isolated followed by overnight fixation in 4% PFA at 4°C. Samples were 432 
decalcified with Osteosoft (Merck) for 10 d before dehydration and cryopreservation in 30% sucrose 433 
followed by cryosectioning. Fourteen µm midmodiolar sections were cut and mounted on Superfrost 434 
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Plus microscopy slides (Thermo Fisher Scientific). The immunofluorescence procedure was 435 
performed using a Shandon Sequenza staining rack (Thermo Fisher Scientific). Sections were 436 
permeabilized for 5 min with 0.1% Triton X-100 and then blocked with a blocking solution (2% BSA 437 
plus 0.01% Triton X-100 in PBS) for 1 h at room temperature. The neuron-specific primary antibody 438 
against β-III Tubulin (TUJ, mono-clonal mouse anti β-III Tubulin, R&D Systems) was diluted 1:500 439 
in blocking solution and incubated overnight at 4°C. The slides were rinsed three times with PBS and 440 
incubated with the secondary antibody (Alexa Fluor 488 conjugated, Invitrogen) diluted 1:500 in 441 
blocking solution for 2 h at room temperature. After washing three times with PBS, the samples were 442 
mounted with a coverslip using Fluoroshield containing DAPI (Sigma). Images of the spiral ganglion 443 
were acquired with a Zeiss Axio Imager M1 with Zeiss EC Plan‐Neofluar objectives using AxioVision 444 
software (AxioVs40 V 4.8.2.0, Carl Zeiss MicroImagin GmbH). 445 
Statistical analysis 446 
Statistical analyses were performed with GraphPad Prism software (Prism 7 for Windows; GraphPad 447 
Software Inc., San Diego, CA). If not stated otherwise, results are presented as mean values ± standard 448 
deviations. To compare data between two groups, an unpaired Student t test was used for parametric 449 
data. For non-parametric data, a Mann-Whitney test was used. For in vitro cytokines and NO release 450 
comparing multiple different groups, Tukey’s multiple comparison test was applied to adjust for 451 
multiple testing. Mortality rates were calculated using log rank (Mantel-Cox) test for significance 452 
based on all infected animals and numbers of animals sacrificed for ethical reasons (clinical score of 2) 453 
or dying spontaneously. In box-plots, the horizontal line within the box represents the median, the top 454 
and bottom of the box mark the 75th and the 25th percentiles, respectively. The upper and lower bound 455 
of the whiskers represent the range of the data. A Pearson correlation was performed to correlate 456 
cochlear occlusion with hearing capacity. A two-tailed p-value of <0.05 was considered statistically 457 
significant, with p<0.05 (*), p<0.01 (**), p<0.001 (***) and p<0.0001 (****). 458 
For exploratory data analysis, a multivariate linear regression model was used to estimate predictors 459 
and determinants for bacterial meningitis-induced hearing loss. The linear coefficients and a 95% 460 
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confidence interval were calculated for each variable. Statistical analyses were performed using 461 
STATA 12 (STATA Corp., College Station, TX). 462 
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Figure legends 739 
Fig. 1 Inflammatory cytokines and nitric oxide (NO) production upon in vitro stimulation of 740 
astroglial cells with living S. pneumoniae. Cytokines and NO were measured in cell culture 741 
supernatant 24 hours after concomitant application of living S. pneumoniae and antibiotics. Infection 742 
and bacteriolysis induced by ceftriaxone (CRO) resulted in high levels of IL-1β (A), IL-6 (B), TNF-α 743 
(D) and NO (F) release, whereas no clear effect was found for IFN-γ (E). All therapies containing 744 
non-bacteriolytic antibiotics significantly reduced the release of inflammatory cytokines compared to 745 
CRO monotherapy (all p<0.01 for CRO vs. DOX; p<0.001 for CRO vs. CRO+DOX, CRO vs. DAP, 746 
CRO vs. CRO+DAP; p<0.0001 for CRO vs. CRO+DOX+DAP). Doxycycline (DOX) monotherapy 747 
and all combination therapies containing daptomycin (DAP) significantly reduced NO production 748 
compared to CRO monotherapy (all p<0.0001). Significance levels are not indicated in the graphs for 749 
clearer representation. Statistical differences were assessed using unpaired t-tests. 750 
 751 
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Fig.2 Clinical data of infant rats during acute pneumococcal meningitis. Combined antibiotic 753 
therapy (n=72) with daptomycin (DAP), doxycycline (DOX) and ceftriaxone (CRO) significantly 754 
improved survival compared to CRO monotherapy (n=71) during acute PM (A). Relative weight 755 
change during acute PM indicates reduced weight gain in infected (PM+) compared to mock-infected 756 
(PM-) animals (n=6 per treatment group). Infected animals with combined adjuvant therapy presented 757 
significantly increased weight change at 42 hpi, compared to CRO monotherapy (B). Clinical scoring 758 
revealed reduced clinical scores in all infected compared to mock-infected animals (C). Differences 759 
were assessed by an unpaired t-test in (B) and (C) and with a Log-rank test to compare survival in A.  760 
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Fig. 3 Inflammatory CSF cytokine levels, cortical necrosis and bacterial clearance from CSF 761 
during the acute PM. Cytokine levels are represented by mean ± 95% confidence interval starting 762 
before treatment initiation, 6 hours and 24 hours after treatment start (representing 18, 24 and 42 hpi) 763 
for IL-1β (A), IL-6 (B), IL-10 (C) and TNF-α (D). Combination adjuvant therapy (n=11) significantly 764 
reduced IL-1β, IL-6 and IL-10 CSF levels compared to CRO monotherapy (n=11), while showing a 765 
trend towards reduced TNF-α CSF level 6 hours after treatment start. Bacterial titers in the CSF were 766 
similar in both treatment groups before starting therapy (at 18 hpi; n=53 for CRO/DAP/DOX, n=49 for 767 
CRO) with a faster bacterial clearance in animals receiving the combined adjuvant therapy (n=17) 768 
compared to CRO monotherapy (n=18, E). Cortical necrosis was only found in animals with PM and 769 
was significantly reduced by combined adjuvant therapy (n=15) compared to CRO monotherapy 770 
(n=15, F). Statistical differences were assessed using an unpaired t-test for cytokines and bacterial titer 771 
at 18 hpi. For necrotic cortex volume and bacterial titer at 24 hpi a Mann-Whitney test was used as 772 
data were not normally distributed. 773 
  774 
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Fig. 4 Hearing capacity assessed three weeks after acute pneumococcal meningitis. 775 
Representative ABR recordings from a mock-infected rat (A) with a hearing threshold of 35dB 776 
compared to an infected rat (B) with an elevated hearing threshold of 65dB. Perceived sound 777 
intensities are indicated with dashed lines. Infected animals receiving combined adjuvant therapy 778 
(n=25) showed a trend towards improved hearing thresholds compared to animals receiving CRO 779 
monotherapy (n=23, C). Combined adjuvant therapy significantly reduced hearing loss in mildly 780 
infected animals (n=10) compared to CRO monotherapy (n=9, D).  781 
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Fig. 5 Immunohistological analysis of spiral ganglion neuron density and cochlear occlusion in 783 
mildly infected animals. (A) Midmodiolar section showing the basal (B), middle (M) and apical (A) 784 
turns of an infected rat three weeks after PM immunostained for neurons (β-III tubulin, green) and cell 785 
nuclei (DAPI, blue). The absence and presence of fibrous occlusion in the perilymphatic space in a 786 
mock-infected control animal and in an infected animal receiving standard CRO monotherapy is 787 
represented in over-exposed immunofluorescence pictures (B). The area with fibrous occlusion in the 788 
perilymphatic space is indicated by white dashed lines. Spiral ganglion neuron (SGN) density was not 789 
significantly different in any of the cochlear turns in infected animals between the two treatment 790 
groups (C). Combined adjuvant therapy (n=10) significantly reduced the amount of fibrous tissue in 791 
the perilymphatic space compared to CRO monotherapy (n=9, D).  A significant positive correlation 792 
for fibrous occlusion of the perilymphatic space and hearing threshold was found (E). 793 
 794 
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Table with legend 796 
Table 1. Univariate and multivariate linear regression for click hearing thresholds three weeks after 797 
surviving an episode of acute pneumococcal meningitis (n=48). 798 
Hearing Thresholds 
 Univariate Multivariate 
 Coef. 95% CI p Coef. 95% CI p 
Bacterial inoculum (per add. log) 70.5 45.6-95.5 <0.001 69.9 48.2-91.6 <0.001 
Comb. Adjuv. Therapy -9.7 -23.8-4.4 0.172 -10.3 -19.9- -0.6 0.037 
Low in-litter mortality -18.1 -31.8- -4.3 0.011 -17.1 -26.9- -7.3 0.001 
Activity @ 24hpi (per add. score) -26.7 -39.5- -14.02 <0.001 - - - 
 799 
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